代谢综合征致病机理及其干预研究

1. Orchard TJ.Becker DJ.Bates M Plasma insulin and lipoprotein concentrations:an atherogenic association? 1983
2. Haffner SM.Fong D.Hazuda HP Hyperinsulinemia,upper body adiposity,and cardiovascular risk factors in non-diabetics 1988
3. World Health Organization Definition,diagnosis,and classification of diabetes mellitus and its complications:Report of a WHO Consultation 1999
4. Expert Panel on the Detection Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) 2001
5. Charles M.Alexander PB.Landsman SM NCEP-defined metabolic syndrome,diabetes,and prevalence of coronary heart disease among NHANES Ⅲ participants 2003
6. Gibbons RJ.Smith S.Antman E American College of Cardiology,American Heart Association.American College of Cardiology/American Heart Association clinical practice guidelines:PartⅠ:Where do they come from ? 2003(23)
7. Gibbons RJ.Smith SC.Antman E American College of Cardiology; American Heart Association.American College of Cardiology/American Heart Association clinical practice guidelines:Part Ⅱ:evolutionary changes in a continuous quality improvement project 2003(24)
8. Astrup A.Toubro S When,for whom and how to use sibutramine? 2001(z4)
9. Ballinger A.Peikin SR Orlistat:its current status as an anti-obesity drug 2002
10. US Department of Health and Human Services Leading health indicators:Overweight and obesity 2000
11. Franz MJ.Bantle JP.Beebe CA Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications 2002
12. Kiortsis DN.Milionis H.Bairaktari H Efficacy of combination of atorvastatin and micronized fenofibrate in the treatment of severe mixed hyperlipidemia 2000
13. Assmann G.Schulte H.von Eckardstein A High-density lipoprotein cholesterol as a predictor of coronary heart disease risk:The PROCAM experience and pathophysiological implications for reverse cholesterol transport 1996(zk)
14. Kiortsis DN.Milionis H.Bairaktari H Efficacy of combination of atorvastatin and micronized fenofibrate in the treatment of severe mixed hyperlipidemia 2000
15. Gordon DJ.Probstfield JL.Garrison RJ High-density lipoprotein cholesterol and cardiovascular disease.Four prospective American studies 1989
16. BIP Group Bezafibrate Infarction Prevention.Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.The Bezafibrate Infarction Prevention(BIP) Study 2000
17. Rubins HB.Robins SJ.Collins D Diabetes,plasma insulin and cardiovascular disease.Subgroup analysis from the Department of Veterans Affairs,highdensity lipoprotein intervention trial(VA-HIT) 2002
18. Wierzbicki AS.Mikhailldis DP.Wray R Statinfibrate combination:therapy for hyperlipidemia:a review 2003
19. Alexandridis G.Pappas GA.Elisaf MS Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil 2000
20. Farmer A.Montori V.Dinneen S Fish oil in people with type 2 diabetes mellitus 2001
21. Guidelines Committee 2003 European Society of Hypertension:European Society of Cardiology guidelines for the management of arterial hypertension 2003
22. Goldstein DJ Beneficial health effects of a modest weight loss 1992
23. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin 2002
24. Ballantyne CM.Olsson AG.Cook TJ Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S 2001
25. Festa A.D'Agostino R Jr.Howard G Chronic subclinical inflammation as part of the insulin resistance syndrome:The Insulin Resistance Atherosclerosis Study(IRAS) 2000
26. Sattar N.Gaw A.Scherbakova O Metabolic syndrome with and without Creactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study 2003
27. Ong HT The statin studies:from targeting hypercholesterolaemia to targeting the high-risk patient 2005
28. Vakkilainen J.George SJ.Aubin AF Relationships between low-density lipoprotein particle size,plasma lipoproteins,and progression of coronary artery disease:the diabetes atherosclerosis intervention study(DAIS) 2003
29. Andre L.Yusuf S.Pogue J Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation(HOPE) Study 2003
30. Patricia I.Takala T.Oikonen V Effect of training status on regional disposal of circulating free fatty acids in the liver and skeletal muscle during physiological hyperinsulinemia 2004
31. Hulthe J.Hulten LM.Fagerberg B Low adipooyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles:atherosclerosis and insulin resistance study 2003
32. Kain K.Catto AJ.Grant PJ Associations between insulin resistance and thrombotic risk factors in high risk South Asian subjects 2003
33. Vgontzas AN.Bixler EO.Chrousos GP Metabolic disturbances in obesity versus sleep apnoea:the importance of visceral obesity and insulin resistance 2003

更多...

1. 阮丽.曾耀星 代谢综合征的新进展与综合防治 [期刊论文] -中国健康教育2008(05)

更多...